{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:31:54Z","timestamp":1773077514415,"version":"3.50.1"},"reference-count":34,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Sports Med"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Exercise induced bronchoconstriction (EIB) is common in elite athletes. Eucapnic voluntary hyperventilation (EVH) is a laboratory test recommended for the identification of EIB in athletes, secondary to a field exercise challenge. Montelukast attenuates EIB, but its protective effect against airway narrowing from EVH has not been investigated.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold>To examine the effectiveness of montelukast after exercise and after EVH.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A randomised, placebo controlled, double blind, crossover study was performed with 11 physically active EIB positive subjects (eight men, three women; mean (SD) age 22.8 (6.8) years). Six hours before each of the following challenges 10 mg montelukast or placebo was ingested: (<jats:italic>a<\/jats:italic>) a six minute, cold air (\u22123\u00b0C) maximal effort work accumulation cycle ergometer exercise; (<jats:italic>b<\/jats:italic>) EVH, breathing 5% CO<jats:sub>2<\/jats:sub>compressed air at 85% maximal voluntary ventilation for six minutes. Spirometry was performed before and 5, 10, and 15 minutes after the challenge. At least 48 hours was observed between challenges.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>No differences in forced expiratory volume in one second (FEV<jats:sub>1<\/jats:sub>) were found after the two challenges. Exercise and EVH resulted in falls in FEV<jats:sub>1<\/jats:sub>of 22.4 (18.0) and 25.6 (16.8) respectively. Falls in FEV<jats:sub>1<\/jats:sub>after montelukast were less than after placebo (10.6 (10.6) and 14.3 (11.3) after exercise and EVH respectively; p&lt;0.05). Montelukast provided protection against bronchoconstriction (59% and 53%; p&lt;0.05) for eight exercising subjects and 10 EVH subjects; no protection was afforded for three exercising and one EVH challenged subject.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>Both exercise and EVH were potent stimuli of airway narrowing. A single dose of montelukast provided reasonable protection in attenuating bronchoconstriction from either exercise or EVH. The similar protection by montelukast suggests that EVH is a suitable laboratory surrogate for EIB evaluation.<\/jats:p>","DOI":"10.1136\/bjsm.2004.014282","type":"journal-article","created":{"date-parts":[[2005,3,25]],"date-time":"2005-03-25T18:22:49Z","timestamp":1111774969000},"page":"232-236","source":"Crossref","is-referenced-by-count":55,"title":["Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise"],"prefix":"10.1136","volume":"39","author":[{"given":"K W","family":"Rundell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B A","family":"Spiering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T M","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2005,3,25]]},"reference":[{"key":"2024051312184287000_39.4.232.1","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-200004000-00003"},{"key":"2024051312184287000_39.4.232.2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.108605"},{"key":"2024051312184287000_39.4.232.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70010-7"},{"key":"2024051312184287000_39.4.232.4","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-200102000-00006"},{"key":"2024051312184287000_39.4.232.5","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.127784"},{"key":"2024051312184287000_39.4.232.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.35.5.344"},{"key":"2024051312184287000_39.4.232.7","first-page":"44","volume":"111","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"2024051312184287000_39.4.232.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.909"},{"key":"2024051312184287000_39.4.232.9","unstructured":"International Olympic Committee Medical Commission. Beta2 adrenoceptor agonists and the Olympic games in Athens. www.olympic.org (accessed January\u2013April 2004)."},{"key":"2024051312184287000_39.4.232.10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00005768-200002000-00010","volume":"32","year":"2000","journal-title":"Med Sci Sports Exerc"},{"key":"2024051312184287000_39.4.232.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.109.6.1520"},{"key":"2024051312184287000_39.4.232.12","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.109822"},{"key":"2024051312184287000_39.4.232.13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1203\/00006450-199105010-00009","volume":"29","year":"1991","journal-title":"Pediatr Res"},{"key":"2024051312184287000_39.4.232.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.1.45"},{"key":"2024051312184287000_39.4.232.15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1139\/y95-028","volume":"73","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"2024051312184287000_39.4.232.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807163390302"},{"key":"2024051312184287000_39.4.232.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70322-2"},{"key":"2024051312184287000_39.4.232.18","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.66"},{"key":"2024051312184287000_39.4.232.19","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3038.2002.02078.x"},{"key":"2024051312184287000_39.4.232.20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/thx.52.2.130","volume":"52","year":"1997","journal-title":"Thorax"},{"key":"2024051312184287000_39.4.232.21","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016056912698"},{"key":"2024051312184287000_39.4.232.22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.ats11-99"},{"key":"2024051312184287000_39.4.232.23","doi-asserted-by":"publisher","DOI":"10.1183\/09041950.053s1693"},{"key":"2024051312184287000_39.4.232.24","first-page":"51","volume":"6","year":"1997","journal-title":"Eur Respir Mon"},{"key":"2024051312184287000_39.4.232.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.5.1240"},{"key":"2024051312184287000_39.4.232.26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/bjsm.32.2.125","volume":"32","year":"1998","journal-title":"Br J Sports Med"},{"key":"2024051312184287000_39.4.232.27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/ajrccm.149.2.8306029","volume":"149","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2024051312184287000_39.4.232.28","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-3838"},{"key":"2024051312184287000_39.4.232.29","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.supplement_2.13tac180"},{"key":"2024051312184287000_39.4.232.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012203232504"},{"key":"2024051312184287000_39.4.232.31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1164\/ajrccm\/145.4_Pt_1.746","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2024051312184287000_39.4.232.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012203232505"},{"key":"2024051312184287000_39.4.232.33","first-page":"461","volume":"21A","year":"1991","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"2024051312184287000_39.4.232.34","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1487"}],"container-title":["British Journal of Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjsm.2004.014282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T19:22:01Z","timestamp":1715628121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjsm.bmj.com\/lookup\/doi\/10.1136\/bjsm.2004.014282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,25]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,3,25]]},"published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1136\/bjsm.2004.014282"],"URL":"https:\/\/doi.org\/10.1136\/bjsm.2004.014282","relation":{},"ISSN":["0306-3674","1473-0480"],"issn-type":[{"value":"0306-3674","type":"print"},{"value":"1473-0480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,25]]}}}